Zenas BioPharma (ZBIO)

• Market cap: $1.05B
• 1 day: 0.33%
• 5 days: -10.66%
• 1 month: -28.52%
• 3 months: -50.05%
• 6 months: -17.7%
• Year to date: -47.04%
• 1 year: 131.27%
• 5 years: 0.66%
• 10 years: 0.66%
• Sector: Healthcare
• Industry: Biotechnology

About: Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.

Employees: 167